Leqvio (Inclisiran) Cannabis Interaction Profile

How Inclisiran Works: The Mechanism That Changes the Interaction Math

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA inside liver cells. After subcutaneous injection, it is taken up by hepatocytes via a GalNAc ligand delivery system, where it silences PCSK9 production for roughly six months [1]. That intracellular, hepatocyte-specific mechanism is fundamentally different from the way most small-molecule cardiovascular drugs work.

The FDA-approved prescribing information for inclisiran confirms that the drug is not a substrate, inhibitor, or inducer of CYP450 enzymes, P-glycoprotein, or major drug transporters [2]. This single pharmacokinetic fact rules out the most common mechanism by which cannabis (tetrahydrocannabinol, THC, and cannabidiol, CBD) interferes with other drugs.

Why CYP450 Independence Matters for Cannabis Users

Cannabis compounds are metabolized primarily by CYP3A4 and CYP2C9, and CBD is a known inhibitor of CYP2C9 and CYP3A4 at higher doses [3]. For drugs that rely on those same enzymes, such as warfarin or tacrolimus, concurrent cannabis use can meaningfully alter plasma concentrations. Inclisiran never enters that enzymatic pathway. Its plasma half-life is roughly 9 hours, after which the pharmacological effect persists for months through the silenced mRNA, not through circulating drug [2].

What the FDA Label Actually Says

The current inclisiran prescribing information lists no cannabis-specific interaction, no cytochrome-mediated interaction warnings, and no dietary restrictions beyond injection-site care [2]. The label's drug interaction section is notably brief compared with statin labels, precisely because the mechanism avoids the hepatic metabolic machinery that generates most cardiovascular drug interactions.

Indirect Cardiovascular Risks When Cannabis Meets an ASCVD Drug

The absence of a pharmacokinetic interaction does not mean cannabis is clinically neutral in a patient prescribed inclisiran. Inclisiran is indicated for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering on top of statin therapy [2]. That population carries substantial baseline cardiac risk, and cannabis places direct stress on the cardiovascular system.

Acute Hemodynamic Effects of Cannabis

Smoked cannabis causes an acute, dose-dependent increase in heart rate of 20 to 50 beats per minute, peaking within 10 to 30 minutes of inhalation [4]. Systolic blood pressure rises transiently then may fall with higher doses, producing orthostatic hypotension in some users. A 2019 analysis published in the Journal of the American College of Cardiology found that cannabis use was independently associated with a 1.5-fold increase in major adverse cardiovascular events (MACE) in patients aged 18 to 44 years with at least one traditional cardiovascular risk factor [5].

For a patient whose reason for taking inclisiran is to reduce MACE risk after a myocardial infarction, that 1.5-fold signal deserves a direct clinician conversation, even if no pill-level drug interaction exists.

Chronic Cannabis Use and Lipid Metabolism

Regular cannabis use shows mixed effects on lipid panels in observational data. A cross-sectional analysis of NHANES data (N=8,479) found that current cannabis users had modestly lower LDL-C and higher HDL-C compared with never-users, but also had higher triglyceride levels [6]. The triglyceride elevation may partially offset the cardiovascular benefit inclisiran is delivering through LDL-C reduction. Clinicians should obtain a full fasting lipid panel, not just LDL-C, at the standard 3-month post-dose monitoring window for patients who use cannabis regularly.

Cardiac Arrhythmia Considerations

Cannabis is associated with atrial fibrillation in case reports and some observational cohorts [7]. A Holter-monitoring substudy cited in a 2020 Circulation review identified a temporal link between cannabis smoking and transient supraventricular tachycardia [7]. Inclisiran itself carries no known proarrhythmic effect, but a patient with ASCVD and concurrent cannabis-induced tachycardia faces compounded risk at the cardiac level that the drug cannot address.

Inclisiran Efficacy Data: Baseline Context for the Interaction Discussion

Understanding what inclisiran actually delivers clinically helps frame why protecting that benefit from indirect cannabis-related cardiovascular harm matters.

ORION-10 and ORION-11 Trial Results

ORION-11 (N=1,617) enrolled adults with ASCVD or ASCVD-equivalent risk plus elevated LDL-C despite maximally tolerated statin therapy. At month 17, inclisiran 284 mg reduced LDL-C by 49.9% compared with placebo (P<0.001) [1]. ORION-10 (N=1,561), which enrolled patients with ASCVD only, showed a 52.3% LDL-C reduction at the same timepoint (P<0.001) [1].

The twice-yearly dosing schedule, confirmed across both trials, is a practical advantage for patients who may have adherence challenges, including those managing chronic cannabis dependence [1].

ORION-4: Ongoing MACE Outcomes Data

ORION-4, a cardiovascular outcomes trial enrolling approximately 15,000 participants across the UK, is designed to report hard MACE endpoints including non-fatal MI, non-fatal stroke, and cardiovascular death [8]. Interim safety data from ORION-4 have not identified any new drug interaction signals as of the most recent published update. Results from the full trial are expected to add clarity to the real-world safety profile in patients with diverse lifestyle exposures, including cannabis use.

CBD-Specific Considerations: Not All Cannabis Products Are Equivalent

Patients often use the terms "cannabis," "marijuana," "THC," and "CBD" interchangeably, but the pharmacology differs in ways that matter for interaction assessment.

CBD and CYP Enzyme Inhibition

CBD inhibits CYP2C9 and CYP3A4 in a dose-dependent manner [3]. A 2020 study in the British Journal of Clinical Pharmacology demonstrated that a single 750 mg CBD dose (comparable to doses used in clinical epilepsy treatment) increased plasma AUC of the CYP2C9 substrate warfarin by approximately 30% [3]. Because inclisiran bypasses these enzymes entirely, the warfarin comparison does not apply to inclisiran. However, if a patient is taking inclisiran alongside a statin or another cardiovascular drug that is a CYP3A4 substrate (such as atorvastatin or simvastatin), CBD use could theoretically affect the statin's plasma concentration, not inclisiran's.

THC vs. Synthetic Cannabinoids

Synthetic cannabinoids (K2, Spice) are not equivalent to delta-9-THC in either pharmacology or cardiovascular risk. Reports of acute MI and stroke in young users of synthetic cannabinoids have appeared in both MMWR and case series in JAMA [9]. Patients who disclose cannabis use should be asked specifically whether they are using plant-derived cannabis or synthetic products, since the cardiovascular risk profile differs substantially.

Can You Drink Alcohol on Leqvio? The Ethanol Interaction Profile

Alcohol does not share a metabolic pathway with inclisiran, so no direct pharmacokinetic interaction between ethanol and inclisiran has been identified in the prescribing information or trial data [2].

Indirect Metabolic Effects of Heavy Alcohol Use

Heavy alcohol use (more than 14 standard drinks per week in men, more than 7 in women, per the NIAAA definition) raises triglycerides, may worsen hepatic steatosis, and can raise blood pressure [10]. Each of these effects partially counteracts the cardiovascular risk reduction inclisiran is providing. Moderate alcohol consumption, defined by the American Heart Association as up to one drink per day for women and two for men, has not been shown to meaningfully interfere with inclisiran's mechanism or efficacy in trial populations [10].

Injection-Site Considerations After Alcohol

There is no clinical evidence that alcohol consumption affects injection-site tolerability for inclisiran. In ORION-10 and ORION-11, injection-site reactions occurred in 2.6% of inclisiran-treated patients versus 1.8% of placebo patients, and no dietary or substance exposure was identified as a modifying factor in the published safety data [1].

Practical Clinical Guidance: What to Tell Patients Who Use Cannabis

The following decision framework consolidates the interaction evidence for use at point of care.

Step 1: Confirm the Cannabis Exposure Type

Ask the patient whether they use smoked flower, vaporized oil, edibles, CBD isolate, or synthetic cannabinoids. The cardiovascular risk and (for co-prescribed drugs) the CYP interaction risk differ across these forms. Document frequency, dose if known, and route.

Step 2: Review the Full Medication List for CYP-Sensitive Co-Prescriptions

Inclisiran itself requires no dose adjustment for cannabis use. However, many patients prescribed inclisiran also take atorvastatin, rosuvastatin, ezetimibe, or antiplatelet agents. Rosuvastatin is minimally metabolized by CYP2C9; atorvastatin is primarily CYP3A4. High-dose CBD use alongside high-dose atorvastatin could theoretically increase atorvastatin exposure, though clinical data on this specific pairing are limited to case reports [3].

Step 3: Assess Cardiovascular Status and Arrhythmia Risk

For patients with recent ACS, heart failure, or documented arrhythmia, the tachycardic and hemodynamic effects of cannabis represent a meaningful clinical concern independent of any drug interaction. The ACC/AHA 2019 guidelines on the primary prevention of cardiovascular disease recommend that clinicians counsel patients on cannabis-related cardiovascular risks during routine preventive visits [11].

Step 4: Monitor Lipids at Standard Intervals Regardless of Cannabis Use

The inclisiran monitoring schedule (lipid panel at approximately 3 months after the first injection, then at each subsequent 6-month injection visit) applies whether or not the patient uses cannabis. Cannabis-related triglyceride elevation may show up on that panel and warrant separate management.

Step 5: Document Disclosure in the Chart

Because cannabis remains a Schedule I controlled substance federally in the United States (though legal in many states), some patients under-report use. Creating a non-judgmental disclosure environment increases the accuracy of the medication history and allows the prescriber to monitor for the indirect cardiovascular effects described above.

Inclisiran Dosing Schedule and Administration Context

Inclisiran is administered as a 284 mg subcutaneous injection by a healthcare provider, not self-administered at home [2]. The schedule is: day 1, day 90 (approximately 3 months), then every 6 months thereafter. This clinic-administered model means that a pharmacist or nurse practitioner sees the patient at every dose, creating a built-in opportunity to review substance use and cardiovascular risk at each visit.

The drug is renally cleared; dose adjustment is not required for mild-to-moderate renal impairment (eGFR 30 to 60 mL/min/1.73m²), though data in severe renal impairment are limited [2]. Cannabis use does not affect renal clearance of inclisiran based on available data.

Special Populations: Cannabis Use in HeFH Patients

Patients with heterozygous familial hypercholesterolemia (HeFH), one of inclisiran's two primary indications, often begin cardiovascular drug therapy in their 20s and 30s, an age group with higher rates of cannabis use. The CDC's National Survey on Drug Use and Health (2022) found that 19.8% of adults aged 18 to 25 reported cannabis use in the past month [12]. Prescribers managing young HeFH patients on inclisiran should integrate cannabis screening into the same counseling workflow used for tobacco and alcohol.

HeFH itself confers a lifetime cardiovascular risk roughly 10 to 20 times that of the general population without treatment [13]. The 49.9% LDL-C reduction from inclisiran in the ORION-11 population is clinically significant in this context, and any lifestyle factor that independently raises cardiovascular event rates, including frequent cannabis use, should be addressed directly.

Summary of the Evidence Field

The direct answer remains consistent across every line of evidence examined: inclisiran and cannabis do not interact pharmacokinetically. The siRNA mechanism, hepatocyte-specific delivery, and absence of CYP450 involvement collectively eliminate the drug metabolism pathway through which most cannabis interactions occur [1, 2, 3]. The clinical concern is cardiovascular, not pharmacokinetic, and it belongs in the same counseling conversation as smoking cessation and dietary cholesterol management.

Patients with ASCVD or HeFH who use cannabis should be informed that their heart is already working against a disease process that inclisiran is actively counteracting, and that cannabis-related tachycardia and blood-pressure instability load the cardiac system in the opposite direction. That conversation does not require a contraindication on a label to be clinically warranted.

Obtain a fasting lipid panel including triglycerides at the 3-month post-first-dose visit for all inclisiran patients, and repeat at every 6-month injection visit for patients who report regular cannabis use.